Skip to content

Annexon ANNX Retained Earnings

Retained Earnings at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$36.42B+12.5%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$377.56M-85.2%
Omeros logo
OmerosOMER
-$857.64M+9.1%
Vor Biopharma logo
Vor BiopharmaVOR
-$1.37B-180%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$637.78M-53.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$3.81B-4.3%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's retained earnings?
Annexon (ANNX) reported retained earnings of -$961.53M in Q1 2026.
How has Annexon's retained earnings changed year-over-year?
Annexon's retained earnings decreased by 25.7% year-over-year, from -$765.06M to -$961.53M.
What is the long-term trend for Annexon's retained earnings?
Over 5 years (2020 to 2025), Annexon's retained earnings has grown at a 40.8% compound annual growth rate (CAGR), from -$165.99M to -$917.39M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.